信立泰：SAL0145药品临床试验申请获受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received an acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0145 injection, which is intended for the treatment of MASH [1] Group 1 - The drug SAL0145 is a self-developed siRNA medication with independent intellectual property rights [1] - The clinical trial application submitted by the company is specifically for SAL0145's use in treating MASH [1]